The role of recombinant Human erythropoietin in neonatal anemia

El-Lahony, Dalia M; Saleh, Nagwan Y.; Habib, Mona Salah El‐din; Shehata, Mohammed; El-Hawy, Mahmoud A.

doi:10.1016/j.hemonc.2019.08.004

Cited by 13 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anemia of prematurity can cause tachycardia, inadequate weight gain, increase oxygen need and apnea or bradycardia (13,27,29). n premature infants, anemia becomes symptomatic when imbalance develops between it's distribution and consumption.…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of Erythrocyte Transfusion in Very Low Birth Weight Infants with Premature Anemia

YAZICI

Bilgin²,

ÖZCAN>³

et al. 2023

Türkiye Çocuk Hast Derg

View full text Add to dashboard Cite

Objective: This study aimed to determine the clinical efficacy of erythrocyte transfusion (ET) in premature infants. Material and Methods: Very low birth weight (VLBW) infants with gestational age (GA) < 32 weeks and/or birth weight (BW) <1500 g and hospitalized in neonatal intensive care unit (NICU) between 2012-2018 were retrospectively evaluated. ET was performed according to Ohls 2007 and Turkish Neonatalogy Society Blood Products Transfusion Guidelines. Results: 72 infants included in this study. Mean BW was 1325 g (680-2290 g), GA was 30 weeks (25-32), median postnatal age was 36.7±26.9 days (8-129), number of ET during hospitalization was 2±1.2 (1-6). There were no significant changes in mean heart rates (p=0.183) and median respiratory rates before and after ET (p=0.123). Weight gain (16 g/day-11 g/day) was statistically similar before and after ET (p=0.861). A significant decrease in apnea, non-invasive ventilation (NIV) and caffeine therapy requirements after ET was determined (p<0.001, p=0.016 and p=0.016). Serum lactate (2.9-1.5) levels were decreased by ET (p=0.017). Conclusion: Premature infants should closely follow-up for anemia and related symptoms during NICU stay. ET may help to decrease frequency of apnea of prematurity, requirements of caffeine therapy and NIV. ET improves tissue oxygenation in VLBW infants with anemia. Decision of ET should be made according to severity of symptoms, and should be performed according to international, national or local transfusion guidelines.

show abstract

Section: Discussionmentioning

confidence: 99%

The Efficacy of Erythrocyte Transfusion in Very Low Birth Weight Infants with Premature Anemia

YAZICI

Bilgin²,

ÖZCAN>³

et al. 2023

Türkiye Çocuk Hast Derg

View full text Add to dashboard Cite

show abstract

“…Además de estimular la eritropoyesis, inhibe la apoptosis en células vasculares y neuronas y regula la angiogénesis; su expresión depende de la presión arterial de oxígeno y está regulada por la hipoxia (40,41). El uso de eritropoyetina humana recombinante (rHu-EPO) como parte del tratamiento de la anemia del prematuro ha sido ampliamente discutido y controvertido, ya que la administración precoz de esta no reduce el número de transfusiones recibidas (5,41,42); sin embargo, hay estudios que demuestran una disminución en la necesidad de transfusiones sanguíneas (13,43,44).…”

Section: Administración Temprana De Agentes Estimulantes De La Eritropoyesisunclassified

Papel de los estimulantes de eritropoyesis en la anemia neonatal

Isaza

Roldan-Tabares

Carvajal-Alzate

et al. 2021

Rev. Fac. Cienc. Salud Univ. Cauca

View full text Add to dashboard Cite

La anemia es una patología comúnmente encontrada en la población neonatal; es secundaria a una serie de factores de riesgo fisiológicos y no fisiológicos que contribuyen a su desarrollo. Entre sus variantes se encuentra la enfermedad hemolítica del feto y el recién nacido, la cual es considerada la causa más frecuente de anemia en dicha población. Se realizó la revisión bibliográfica en las bases de datos Medline, Science Direct y Lilacs hasta agosto de 2020. En la búsqueda y selección de los artículos se usaron los términos MeSH: anemia neonatal, eritroblastosis fetal y eritropoyetina. Para el tratamiento de dicha patología se dispone de a transfusión de glóbulos rojos y los agentes estimulantes de la eritropoyesis; el uso de eritropoyetina humana recombinante como parte del tratamiento ha sido ampliamente discutido y controvertido, no bstante, hay estudios que demuestran que su uso reduce la necesidad de transfusiones sanguíneas.

show abstract

“…Multiple studies have reported on the use of rEPO in extremely low gestational age neonates (ELGANs) to stimulate erythropoiesis and decrease the need for red blood cell transfusions. 4,[7][8][9][10][11][12][13][14] Previous trials have demonstrated that the administration of erythropoietin may reduce the need for future red blood cell transfusions, thereby reducing the risk of development of complications related to transfusion administration. 7,8 There is prospective data to both support and discourage the use of erythropoietin in preterm infants.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of erythropoietin for the late treatment of anemia of prematurity in a level IV neonatal intensive care unit: A retrospective single-center cohort study

Connolly,

Marasch,

McClary

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective To determine the average change in hematocrit (Hct) after erythropoietin administration for the treatment of anemia of prematurity and describe the population in which erythropoietin is being utilized. Study Design This retrospective chart review study included infants who received erythropoietin for the treatment of anemia of prematurity. Results There were 132 infants representing 162 unique treatment courses included in the study. The average change in Hct was 6.2% (SD 3.9%, p<0.001). The average duration of therapy was 9 days (±7) and 6 doses (±2). Rise in Hct was associated with a higher number of EPO doses (P<0.001) and higher postmenstrual age (p<0.001). In our small cohort we did not find an association between the number of rEPO doses and retinopathy of prematurity (ROP) requiring treatment. Conclusion Erythropoietin is safe and effective at treating anemia of prematurity as evidenced by a clinically and statistically significant increase in Hct from baseline.

show abstract

The role of recombinant Human erythropoietin in neonatal anemia

Cited by 13 publications

References 33 publications

The Efficacy of Erythrocyte Transfusion in Very Low Birth Weight Infants with Premature Anemia

The Efficacy of Erythrocyte Transfusion in Very Low Birth Weight Infants with Premature Anemia

Papel de los estimulantes de eritropoyesis en la anemia neonatal

Efficacy of erythropoietin for the late treatment of anemia of prematurity in a level IV neonatal intensive care unit: A retrospective single-center cohort study

Contact Info

Product

Resources

About